Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 10:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 2,997 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo comparator (IV) Clear all
Completed Not applicable Interventional Results available

Antibiotic Prophylaxis in Orthopaedic Traumatology

NCT00610987
View directory record Official record
Conditions
Fractures, Closed, Wounds and Injuries
Interventions
cefazolin, Placebo
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 12, 2015 · Synced Oct 3, 2026, 10:56 PM EDT
Completed Phase 1 Interventional

Effect of Ghrelin on Glucose Metabolism After Bariatric Surgery

NCT02953587
View directory record Official record
Conditions
Obesity
Interventions
Oral Glucose Tolerance Test (OGTT), Human Ghrelin, Saline
Procedure · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 3, 2026, 10:56 PM EDT
Completed Phase 4 Interventional Results available

Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhibitor Treatment

NCT02708355
View directory record Official record
Conditions
Heartburn
Interventions
Esomeprazole 20 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
22 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 3, 2026, 10:56 PM EDT
Completed Phase 3 Interventional Results available

A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)

NCT03066778
View directory record Official record
Conditions
Small Cell Lung Cancer (SCLC)
Interventions
Pembrolizumab, Normal saline solution, Carboplatin, Cisplatin, Etoposide
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
27
States / cities
Miami, Florida • Chicago, Illinois • Evanston, Illinois + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Oct 3, 2026, 10:56 PM EDT
Terminated Phase 4 Interventional Results available

Inflammation-Induced CNS Glutamate Changes in Depression

NCT03004443
View directory record Official record
Conditions
Depression
Interventions
Infliximab, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 3, 2026, 10:56 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease

NCT05068284
View directory record Official record
Conditions
Crohn's Disease
Interventions
ABBV-154, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
45
States / cities
Dothan, Alabama • Mobile, Alabama • Coronado, California + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 3, 2026, 10:56 PM EDT
Terminated Phase 3 Interventional Results available

ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

NCT00272987
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
lapatinib, paclitaxel, trastuzumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
14
States / cities
Roswell, Georgia • Joliet, Illinois • Detroit, Michigan + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Oct 3, 2026, 10:56 PM EDT
Completed Phase 3 Interventional Results available

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

NCT00110019
View directory record Official record
Conditions
Mucosal Melanoma, Recurrent Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Placebo, Sorafenib Tosylate
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
823 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
218
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Little Rock, Arkansas + 175 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 3, 2026, 10:56 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Sleep Health, Inflammation, and Emotion Study

NCT02270619
View directory record Official record
Conditions
Depression
Interventions
Endotoxin, Partial sleep deprivation, Placebo, Uninterrupted sleep
Biological · Behavioral · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
60 Years to 80 Years · Female only
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 3, 2026, 10:56 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART

NCT03787095
View directory record Official record
Conditions
HIV Infections
Interventions
Cemiplimab, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Birmingham, Alabama • San Diego, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 3, 2026, 10:56 PM EDT
Completed Phase 2 Interventional Results available

Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis

NCT02647866
View directory record Official record
Conditions
Ulcerative Colitis, Digestive System Diseases, Colitis, Ulcerative, Colitis, Gastrointestinal Diseases, Inflammatory Bowel Diseases, Intestinal Diseases, Colonic Diseases, Autoimmune Disease, Abdominal Pain
Interventions
KHK4083, Placebo
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2024 · Synced Oct 3, 2026, 10:56 PM EDT
Completed Phase 3 Interventional Results available

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

NCT03675737
View directory record Official record
Conditions
Stomach Neoplasms
Interventions
Pembrolizumab, Cisplatin, 5-fluorouracil, oxaliplatin, capecitabine, Placebo for Pembrolizumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
10
States / cities
Los Angeles, California • Orange, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 3, 2026, 10:56 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade

NCT07459166
View directory record Official record
Conditions
Fentanyl Overdose, Fentanyl Poisoning
Interventions
Naloxone Hydrochloride, Fentanyl, Sterile Saline, CS-1103
Drug
Lead sponsor
Clear Scientific, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 3, 2026, 10:56 PM EDT
Completed Phase 1 Interventional

Iloprost in Preventing Lung Cancer in Former Smokers

NCT02237183
View directory record Official record
Conditions
Lung Carcinoma
Interventions
Iloprost, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 85 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 3, 2026, 10:56 PM EDT
Completed Phase 2 Interventional Results available

Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants

NCT03281577
View directory record Official record
Conditions
Diabetic Gastroparesis, Idiopathic Gastroparesis
Interventions
TAK-954, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 3, 2026, 10:56 PM EDT
Completed Phase 3 Interventional Results available

A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC

NCT02106494
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
APF530, Ondansetron, Ondansetron placebo, APF530 placebo, Fosaprepitant, Dexamethasone
Drug
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years to 87 Years
Enrollment
942 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Phoenix, Arizona • Downey, California • Riverside, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 3, 2026, 10:56 PM EDT
Completed Phase 2 Interventional Results available

A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection

NCT01147302
View directory record Official record
Conditions
Graft Rejection
Interventions
Placebo, C1 Esterase Inhibitor (Human)
Biological
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 3, 2026, 10:56 PM EDT
Completed Not applicable Interventional

Acetaminophen for Oxidative Stress After Cardiopulmonary Bypass

NCT01228305
View directory record Official record
Conditions
Congenital Heart Disease, Cardiopulmonary Bypass
Interventions
Acetaminophen
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
1 Day to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 3, 2026, 10:56 PM EDT
Completed Phase 2 Interventional Results available

Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

NCT01064622
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions
Gemcitabine Hydrochloride, Hydrocortisone/Placebo, Vismodegib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
21 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
25
States / cities
Beverly Hills, California • Duarte, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 3, 2026, 10:56 PM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease

NCT02574637
View directory record Official record
Conditions
Crohn's Disease
Interventions
Brazikumab IV Infusion, Brazikumab SC Injection, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
52
States / cities
Phoenix, Arizona • Lone Tree, Colorado • Clearwater, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 3, 2026, 10:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB133 (Dapirolizumab Pegol) in Healthy Japanese and Caucasian Participants

NCT04571424
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BIIB133 (Dapirolizumab pegol), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 3, 2026, 10:56 PM EDT
Completed Phase 2 Interventional

Double Blind Trial in Children With Autism Spectrum Disorder

NCT06058962
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Suramin Sodium
Drug
Lead sponsor
Paxmedica
Industry
Eligibility
4 Years to 17 Years · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 3, 2026, 10:56 PM EDT
Completed Phase 2 Interventional

CCI-779 in Treating Patients With Prostate Cancer

NCT00012142
View directory record Official record
Conditions
Prostate Cancer
Interventions
temsirolimus
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 3, 2026, 10:56 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia Repair

NCT00528970
View directory record Official record
Conditions
Ileus
Interventions
MOA-728, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
75
States / cities
Benton, Arkansas • Colton, California • Laguna Hills, California + 62 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 3, 2026, 10:56 PM EDT